Details

Autor(en) / Beteiligte

• Pose, Elisa, MD
• Solà, Elsa, MD, PhD
• Piano, Salvatore, MD, PhD
• Gola, Elisabetta, MD
• Graupera, Isabel, MD
• Guevara, Mónica, MD, PhD
• Cárdenas, Andrés, MD, PhD
• Angeli, Paolo, MD, PhD
• Ginès, Pere, MD, PhD

Titel

Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience

Ist Teil von

• The American journal of medicine, 2017-03, Vol.130 (3), p.372-375

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Abstract Background Vaptans, vasopressin selective V2-receptor antagonists, represent the first pharmacologic approach to the treatment of hypervolemic hyponatremia in cirrhosis. However, information on the use of vaptans for patients with cirrhosis and hyponatremia in a real-life scenario is limited. Therefore, this study evaluated the effect of tolvaptan on serum sodium in patients with cirrhosis and severe hypervolemic hyponatremia. Methods Nine patients with cirrhosis and serum sodium ≤125 mEq/L were included. Results Only 2 of the 9 patients (22%) gained an increase in serum sodium >130 mEq/L that persisted throughout treatment. In the remaining patients, serum sodium did not change or increased during the first days but decreased thereafter despite continuation of treatment. Only 1 patient developed hyperkalemia as a side effect. Conclusions The efficacy of tolvaptan in patients with cirrhosis and severe hypervolemic hyponatremia seems to be limited.